We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.04% | 1,334.50 | 1,334.00 | 1,335.00 | 1,337.50 | 1,333.00 | 1,335.00 | 246,975 | 08:35:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.22 | 55.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
23/1/2023 12:10 | The RSI is very low so this might be near the bottom of the cycle. A good time to top up? No idea. | netcurtains | |
20/1/2023 13:36 | OK thanks, didn't know he'd edited his original query. My response to that is correct so if you want to mark it, it should be up not down. 🤡 | anhar | |
20/1/2023 11:53 | netcurtains: Debt was requested, see post 31420 from MK19 which says: How much debt does GSK carry now? I merely answered his question. The figures I stated are shown in the accounts for GSK Q3 2022, being the latest available. He wasn't asking about "liabilities" but specifically about debt which is why I said that other answers were incorrect. I don't see what there is to argue about. I'd add that third party databases are not the most reliable source of information like this. Always best to go back to the actual accounts for the latest and most dependable figures. As to why anyone would want to know that, the level of debt and consequent gearing are important facts for share analysis. | anhar | |
20/1/2023 09:27 | Liability and litigation not helping . Hopefully a take over by summer | alibizzle | |
19/1/2023 15:36 | anhar: Re debt: INCORRECT? How do you work that out? I never gave any figures for debt (he did not ask for it) - he asked for liabilities (and Assets) If you want debt: Its £20B LONG term debt and £3B short-term debt Off-set by £8.5 B cash (eg cash is more than twice short-term debt). Why anyone should be interested in that I dont know. | netcurtains | |
19/1/2023 15:19 | The above figures are incorrect for GSK debt. As at 30.09.22, the latest available, net debt was £18.4bn. This comprised gross debt of £22.1bn less cash and liquid investments of £3.7bn. "Liabilities" is far more than debt because it includes trade creditors etc. | anhar | |
19/1/2023 14:38 | MK19 - If you want the full picture Wall Street Journal gives the full accounts Total Assets £79B total Liabilities £57.7B | netcurtains | |
19/1/2023 14:31 | Yes, HLN has ~£10.8bn | tradermichael | |
19/1/2023 13:52 | More than HLN? Right? | mj19 | |
19/1/2023 12:10 | Total liabilities: ~$60bn | tradermichael | |
19/1/2023 10:10 | How much debt does GSK carry now? | mj19 | |
19/1/2023 09:51 | TM: I must admit I'm quite naive when it comes to GSK. I just look at the share price graph and assume its going up. But nice to have the positive business stuff too. Thanks. | netcurtains | |
19/1/2023 09:03 | Well, I'm always optimistic and especially given the strength of the current pipeline of new entities. In the short term, I'm looking for some positive signs from the Q4 results. | tradermichael | |
18/1/2023 15:05 | Thanks Michael . When do you see a step change upwards in the share price ? | alibizzle | |
18/1/2023 14:36 | Earnings per Share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. | tradermichael | |
18/1/2023 13:29 | Ah ok , what's EPS? | alibizzle | |
18/1/2023 12:47 | Possible doubts about Q4 earnings. Can this be matched: '21 Q4 EPS beaten by 9% '22 Q1 EPS beaten by 174% '22 Q2 EPS beaten by 16% '22 Q3 EPS beaten by 20% '22 Q4 results due 01 Feb ? | tradermichael | |
18/1/2023 12:08 | Sizeable fall today , possible due to bad forecast from banks about GSK projected sp | alibizzle | |
18/1/2023 09:45 | Morgan Stanley really needs to find something else to say was that worth it?And they never say a reason!!! | mj19 | |
18/1/2023 08:13 | 16 Jan 2023 07:41amGSK : MORGAN STANLEY CUTS TARGET PRICE TO 1520P FROM 1535PThis news story contains no content | mj19 | |
18/1/2023 08:10 | Heading back to the 1300s | spoole5 | |
14/1/2023 10:15 | Do you think after we hopefully have some good news in Florida next month with litigation that share price will start really picking up , or is there another event which may precipitate a step change ( other than a take over ) | alibizzle | |
13/1/2023 13:41 | Good expression . All the analysts such as JP Morgan say at best £15 in 2023 . | alibizzle |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions